# OnCo record tisotumab-vedotin (drug). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix owl: <http://www.w3.org/2002/07/owl#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/drugs/tisotumab-vedotin/>
  a schema:Drug ;
  onco:kind "drug" ;
  schema:identifier "tisotumab-vedotin" ;
  schema:name "Tisotumab vedotin"@en ;
  schema:description "Tisotumab vedotin is an ADC against tissue factor, the first to show a survival benefit in recurrent cervical cancer."@en ;
  schema:url <https://onco.cc/drugs/tisotumab-vedotin/> ;
  schema:dateModified "2026-09-04"^^xsd:date ;
  schema:sameAs <https://en.wikipedia.org/wiki/Tisotumab_vedotin> ;
  owl:sameAs <http://www.wikidata.org/entity/Q108670929> ;
  schema:citation <https://dailymed.nlm.nih.gov/dailymed/search.cfm?query=Tisotumab%20vedotin> ;
  onco:status "approved" ;
  onco:modality "ADC" ;
  schema:alternateName "Tivdak" ;
  onco:approval "US 2021: Recurrent/metastatic cervical cancer after chemotherapy (full 2024)", "EU 2025: Recurrent/metastatic cervical after systemic therapy; 28 Mar 2025" ;
  onco:acceleratedApproval "US 2021-09-20: Treatment of adult patients with recurrent or metastatic cervical cancer with disease progression on or after chemotherapy" ;
  onco:acceleratedApprovalConfirmed "US 2024-04-29: Treatment of adult patients with recurrent or metastatic cervical cancer with disease progression on or after chemotherapy" ;
  onco:cancers <https://onco.cc/cancers/cervical/>, <https://onco.cc/cancers/recurrent-metastatic-cervical-cancer/> ;
  onco:technologies <https://onco.cc/technologies/adc/> ;
  onco:targets <https://onco.cc/targets/tissue-factor/> ;
  onco:companies <https://onco.cc/companies/pfizer/>, <https://onco.cc/companies/genmab/> ;
  onco:terms <https://onco.cc/terms/mc-vc-pabc/> ;
  onco:trials <https://onco.cc/trials/nct06459180/>, <https://onco.cc/trials/nct03485209/> .